NASDAQ
26.68USD
+0.23 (+0.87%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
424M
P/E
—
EPS
—
Beta
1.08
52W range
20.23-39.71
Day range
26.36–27.12
Open
27.07
Prev close
26.45
Volume
119.8K
Avg volume
208.7K
Dividend
0.00
IPO
2010-12-17
https://seekingalpha.com/article/4923211-assembly-biosciences-a-gilead-backed-antiviral-option-with-more-embedded-leverage-than-the-market-appreciates · 7/18/2026+0.80
https://seekingalpha.com/article/4904316-assembly-biosciences-inc-asmb-presents-at-bank-of-america-global-healthcare-conference-2026 · 5/14/2026+0.10
https://seekingalpha.com/article/4884593-assembly-biosciences-buy-on-hpi-program-opt-in-and-hdv-candidate-development · 3/20/2026+0.80
https://www.businesswire.com/news/home/20251222410533/en/Gilead-Sciences-Exercises-Option-to-License-Assembly-Biosciences%E2%80%99-Helicase-Primase-Inhibitor-Programs-for-Recurrent-Genital-Herpes/ · 12/22/2025+0.70
https://www.globenewswire.com/news-release/2025/12/08/3201967/16259/en/Assembly-Biosciences-Reports-Positive-Interim-Results-from-Phase-1b-Clinical-Studies-of-Long-Acting-Helicase-Primase-Inhibitor-Candidates-ABI-1179-and-ABI-5366-Showing-Reductions-i.html · 12/8/2025+1.00
https://www.benzinga.com/markets/equities/25/09/47912014/4-biotechnology-stocks-that-outshine-in-momentum-amid-strong-technicals · 9/29/2025+1.00
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
